Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Operating expenses:        
Research and development $ 824,094 $ 168,992 $ 1,368,396 $ 318,963
General and administrative 1,072,169 1,553,391 2,214,712 3,730,960
Total operating expenses 1,896,263 1,722,383 3,583,108 4,049,923
Operating loss (1,896,263) (1,722,383) (3,583,108) (4,049,923)
Change in fair value of common stock warrants (152,447)   (152,447)  
Warrant financing expense (192,817)   (192,817)  
Other income (expense), net 38 (16,671)
Loss before income taxes (2,241,489) (1,722,383) (3,945,043) (4,049,923)
Income taxes
Net loss (2,241,489) (1,722,383) (3,945,043) (4,049,923)
Deemed dividends attributable to Series A Preferred Stock (2,568,132)   (2,568,132)  
Net loss applicable to common stockholders $ (4,809,621) $ (1,722,383) $ (6,513,175) $ (4,049,923)
Loss per common share - basic and diluted (in dollars per share) $ (0.64) $ (0.67) $ (1.15) $ (1.63)
Weighted average shares outstanding, basic and diluted (in shares) 7,476,046 2,587,871 5,641,671 2,485,853